HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dong Yin Selected Research

luteolin-7-glucoside

1/2022Luteoloside protects the vascular endothelium against iron overload injury via the ROS/ADMA/DDAH II/eNOS/NO pathway.
6/2018Luteoloside attenuates anoxia/reoxygenation-induced cardiomyocytes injury via mitochondrial pathway mediated by 14-3-3η protein.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dong Yin Research Topics

Disease

43Neoplasms (Cancer)
10/2022 - 03/2004
20Myocardial Infarction
01/2022 - 11/2016
15Thrombosis (Thrombus)
01/2022 - 06/2014
13Hemorrhage
01/2022 - 11/2014
13Hypoxia (Hypoxemia)
01/2021 - 10/2013
13Breast Neoplasms (Breast Cancer)
01/2020 - 06/2005
10Glioma (Gliomas)
01/2020 - 11/2002
9Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 10/2013
9Glioblastoma (Glioblastoma Multiforme)
10/2019 - 01/2005
8Iron Overload
01/2022 - 04/2013
7Death (Near-Death Experience)
01/2022 - 11/2016
6Coronary Artery Disease (Coronary Atherosclerosis)
01/2022 - 01/2019
6Body Weight (Weight, Body)
12/2020 - 04/2013
6Hepatocellular Carcinoma (Hepatoma)
01/2019 - 04/2013
6Carcinogenesis
11/2017 - 03/2004
5Neoplasm Metastasis (Metastasis)
07/2022 - 06/2013
5Mitochondrial Diseases (Mitochondrial Disease)
01/2021 - 01/2017
5Brain Neoplasms (Brain Tumor)
10/2019 - 11/2002
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2022 - 09/2010
4Lung Neoplasms (Lung Cancer)
07/2022 - 01/2006
4Ischemia
11/2021 - 03/2015
4Cardiotoxicity
11/2021 - 08/2018
4Type 2 Diabetes Mellitus (MODY)
08/2021 - 02/2015
4Infections
01/2021 - 01/2018
3Diabetic Nephropathies (Diabetic Nephropathy)
08/2021 - 01/2019
3Infarction (Infarctions)
01/2021 - 03/2015
3Pathologic Dilatation (Ectasia)
01/2021 - 11/2016
3Esophageal Squamous Cell Carcinoma
01/2020 - 12/2007
3Prostatic Neoplasms (Prostate Cancer)
01/2020 - 06/2005
3Pathologic Processes
01/2020 - 01/2018
3Reperfusion Injury
03/2015 - 10/2013
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2013 - 01/2006
2Renal Cell Carcinoma (Grawitz Tumor)
03/2022 - 01/2020
2Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 01/2016
2Osteosarcoma (Osteogenic Sarcoma)
10/2021 - 01/2018
2Melanoma (Melanoma, Malignant)
02/2021 - 05/2004
2Heart Failure
01/2021 - 02/2009
2Diabetes Mellitus
01/2021 - 01/2020
2Wounds and Injuries (Trauma)
12/2020 - 12/2018
2Stroke (Strokes)
10/2020 - 01/2020
2Drug-Related Side Effects and Adverse Reactions
06/2020 - 07/2009

Drug/Important Bio-Agent (IBA)

17Proteins (Proteins, Gene)FDA Link
10/2021 - 03/2004
11omega-Chloroacetophenone (Mace)IBA
01/2022 - 01/2017
92'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
01/2022 - 01/2020
8Biological ProductsIBA
12/2020 - 03/2004
7DNA (Deoxyribonucleic Acid)IBA
01/2020 - 04/2004
7Messenger RNA (mRNA)IBA
02/2015 - 01/2003
6RNA (Ribonucleic Acid)IBA
01/2022 - 02/2015
6IronIBA
01/2022 - 04/2013
6Biomarkers (Surrogate Marker)IBA
11/2021 - 01/2016
6Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021 - 01/2018
6MicroRNAs (MicroRNA)IBA
01/2021 - 09/2016
5Circular RNAIBA
10/2022 - 01/2020
5Reactive Oxygen Species (Oxygen Radicals)IBA
11/2020 - 04/2013
5Long Noncoding RNAIBA
01/2020 - 10/2017
5Connective Tissue Growth FactorIBA
06/2011 - 10/2005
5cucurbitacin BIBA
09/2010 - 09/2008
41- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2022 - 04/2013
4Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
05/2021 - 01/2020
4Clopidogrel (Plavix)FDA Link
05/2021 - 01/2020
4Transcription Factors (Transcription Factor)IBA
01/2021 - 01/2007
4Capsaicin (Zostrix)FDA Link
01/2021 - 01/2017
4Pharmaceutical PreparationsIBA
01/2017 - 02/2007
3Lipoprotein(a)IBA
01/2022 - 01/2021
3Blood Glucose (Blood Sugar)IBA
01/2022 - 01/2019
3L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2021 - 03/2015
3Small Interfering RNA (siRNA)IBA
01/2021 - 06/2004
3Creatine Kinase (Creatine Phosphokinase)IBA
01/2021 - 03/2015
3Mitochondrial Permeability Transition PoreIBA
11/2020 - 04/2013
3Caspase 3 (Caspase-3)IBA
11/2020 - 07/2009
3CateninsIBA
09/2020 - 05/2015
3Estrogen ReceptorsIBA
01/2020 - 06/2005
3Sirtuin 1IBA
01/2017 - 08/2015
3Bortezomib (Velcade)FDA Link
10/2015 - 01/2005
3Proteasome InhibitorsIBA
10/2015 - 01/2005
3VorinostatFDA Link
08/2007 - 01/2006
3Histone Deacetylase InhibitorsIBA
08/2007 - 01/2006
2Matrix Metalloproteinases (MMPs)IBA
01/2022 - 01/2019
2Glucose (Dextrose)FDA LinkGeneric
01/2022 - 08/2021
2luteolin-7-glucosideIBA
01/2022 - 06/2018
2Cadherins (E-Cadherin)IBA
11/2021 - 08/2007
2CCAAT-Enhancer-Binding ProteinsIBA
08/2021 - 01/2020
2TOR Serine-Threonine KinasesIBA
01/2021 - 01/2019
2Thymidine Monophosphate (TMP)IBA
01/2021 - 06/2020
2CytokinesIBA
01/2021 - 12/2019
2tetramethylpyrazineIBA
06/2020 - 01/2019
2ResveratrolIBA
03/2020 - 03/2015
2QuercetinIBA
02/2020 - 10/2013
2CreatinineIBA
01/2019 - 01/2019
2Anti-Bacterial Agents (Antibiotics)IBA
12/2018 - 01/2018
2Alanine Transaminase (SGPT)IBA
10/2018 - 04/2013
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
10/2018 - 04/2013

Therapy/Procedure

24Therapeutics
01/2022 - 01/2005
16Stents
04/2022 - 01/2017
14Percutaneous Coronary Intervention
01/2022 - 03/2017
5Drug-Eluting Stents
01/2022 - 01/2020
5Drug Therapy (Chemotherapy)
01/2019 - 01/2006
3Neoadjuvant Therapy
01/2020 - 12/2012
2Decompression
07/2022 - 11/2007
2Molecular Targeted Therapy
10/2021 - 10/2015